Lilly sues six companies over black-market retatrutide sales

Eli Lilly filed six lawsuits against U.S. companies selling black-market versions of its experimental obesity drug retatrutide, which remains unapproved by any regulator worldwide.

"What is being sold on the black market is not a medicine – it is entirely unverified, unapproved and not worth the risk," David A. Hyman, M.D., Lilly's chief medical officer, said.

The lawsuits target compounding pharmacies, medical spas and online sellers, including Aesthetic Envy Cosmetic Centers, Astra LLC, Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide Co. Lilly has referred more than 200 individuals and entities to the FDA, the U.S. Justice Department, state attorneys general, law enforcement and professional licensing boards, and reported more than 14,000 websites, advertisements, social media posts and product listings that unlawfully market retatrutide in over 100 countries.

Retatrutide is in Phase 3 clinical trials for obesity, type 2 diabetes and related indications, and no medicine containing it has been approved for human use. The FDA has said sales of unapproved retatrutide are illegal and cannot lawfully be compounded, and that so-called "research-use only" products are of unknown quality. U.S. Customs and Border Protection intercepted more than 690 shipments totaling over 31,000 units of illicit GLP-1 drugs in fiscal 2025; in July alone seizures more than doubled to over 1,400, with nearly 90,000 vials intercepted.

"Every single time that someone takes one of these, they're exposing themselves to a huge amount of risk," said Dr. Max Denning, Lilly's associate vice president and therapeutic area lead for global patient safety in cardiometabolic health.

Lilly is also calling on social media and e-commerce platforms, credit card companies, payment processors and shipping carriers to help shut down the sellers' operations. The company said some platforms continue to amplify misleading content to vulnerable consumers despite its reports, even as sellers present themselves as "medical spas" and "wellness clinics" while sourcing products from unregulated foreign manufacturers.

The enforcement push signals Lilly is defending the commercial value of retatrutide, a potential blockbuster in an obesity market where demand has fueled a thriving online black market. Investors will watch whether the lawsuits and regulatory referrals deter unauthorized sellers before the drug's expected regulatory review.

This article is for informational purposes only and does not constitute investment advice.